- FoI Number
- 2025-160
- Subject
- Oncology Breast Cancer
- Date Received
- 03/06/2025
- Request and Response
-
- How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:
- Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Alpelisib + Fulvestrant
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel
- Atezolizumab
- Capivasertib
- Capecitabine as a single agent
- Carboplatin + Paclitaxel
- Elacestrant
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fulvestrant as a single agent
- Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
- Palbociclib + Fulvestrant
- Parp Inhibitors (Olaparib/Talazoparib)
- Pembrolizumab Monotherapy
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Pembrolizumab
- Carboplatin + Paclitaxel + Pembrolizumab
- Pertuzumab (Perteja) + Trastuzumab (Herceptin)
- Phesgo (Pertuzumab + Trastuzumab in a single injection)
- Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Sacituzumab Govitecan
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Trastuzumab deruxtecan (Enhertu)
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel
- Trastuzumab emtansine (Kadcyla)
- Any other active systemic anti-cancer therapy
- Aromatase Inhibitor as a single agent
- How many patients have been treated for metastatic breast cancer in the past 3 months with the following systemic anti-cancer therapies?
- Phesgo (Pertuzumab + Trastuzumab in a single injection)
- Pertuzumab (Perteja) + Trastuzumab (Herceptin)
- Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel
- Trastuzumab deruxtecan (Enhertu)
- Trastuzumab emtansine (Kadcyla)
- Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Capecitabine as a single agent
- Carboplatin + Paclitaxel
- Carboplatin + Paclitaxel + Pembrolizumab
Given the small numbers of patients involved; the specific and sensitive nature of the health conditions referred to; the size of Shetland’s population; the specific treatments; and the short timeframe, NHS Shetland considers that providing any answers to questions 1 and 2 carries a high risk of identifying individuals. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.
- Does your trust participate in any Clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.
No. Trials are carried out by NHS Grampian
